NICE approves Trabectedin
pharmafile | January 19, 2010 | News story | Sales and Marketing | NICE, PharmaMar, Trabectedin, soft tissue sarcoma
Patients with advanced soft tissue sarcoma could now benefit from PharmaMar’s new drug trabectedin, after the NICE granted its approval.
Soft tissue sarcoma develops in the body’s soft supportive tissue – such as fat, muscle and blood vessels – and affects around 2,000 people a year in the UK.
Trabectedin works by damaging the DNA in cancer cells, preventing them from growing and spreading to other parts of the body.
Research suggests that the drug may extend life by at least three months more than other NHS treatments and that it may therefore be beneficial for some of the 500-600 people in England and Wales with advanced soft tissue sarcoma.
NICE had initially ruled that trabectedin would not be a cost-effective use of NHS resources, but it has since changed its mind thanks to a cost-sharing scheme agreed with PharmaMar.
The drug has now been recommended in the institute’s final draft guidance, with the NHS paying for each patient’s first five treatment cycles and PharmaMar funding any cycles beyond this.
Under the latest guidance, the drug is recommended as a treatment for people with advanced soft tissue sarcoma who have previously failed to respond to treatment with anthracyclines and ifosfamide, or who are unable to tolerate those treatments.
Dr Carole Longson, director at the NICE Health Technology Evaluation Centre, said the ruling was not easy to make because soft tissue sarcoma is a rare cancer and the evidence was limited.
But she added: “However, treatment options for this type of cancer are limited and in the last 20 years there have been no major developments to treat the advanced stages of this disease. Being able to recommend trabectedin for use on the NHS represents a step forward in the care of this group of patients who may have very few treatment options left.”
The decision has been welcomed by patient organisation Sarcoma UK.
Director Roger Wilson commented: “I am delighted that trabectedin has been approved. This drug benefits a large proportion of the small number of patients who receive it.”
Hilary Tovey, Cancer Research UK’s policy manager, said that the decision is “great news for people with advanced soft tissue sarcoma”. “We are delighted with this decision and pleased to see manufacturers responding to opportunities to make their drugs available on the NHS,” she added.
Related Content
Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
